All In Biotech

Drug Trial Radar · NCT05612035

Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

129

Actual

Start

Mar 16, 2023

Primary completion

Apr 9, 2026

Study completion May 1, 2027

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Nov 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.

Conditions

  • Pulmonary Hypertension
  • Chronic Obstructive Pulmonary Disease

Interventions

  • FrespaciguatDrug

    Frespaciguat 380 µg administered as dry powder inhalation once daily.

  • PlaceboDrug

    Placebo administered as dry powder inhalation once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in 6-minute Walk Distance (6MWD) at Week 24Time frame: Baseline and Week 24

Locations

85 sites in 19 countries. Site status is shown where the registry gives one.

  • UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110)

    San Francisco, California

  • University of Colorado Anschutz Medical Campus-University of Colorado Hospital Cardiac and Vascular ( Site 0101)

    Aurora, Colorado

  • Clinovation Intl. Corp. ( Site 0108)

    Sebring, Florida

  • Alexian Brothers Medical Center-Pulmonary ( Site 0109)

    Elk Grove Village, Illinois

  • University of Iowa ( Site 0103)

    Iowa City, Iowa

  • University of Kansas Medical Center-IM-Pulmonary and Critical Care Medicine ( Site 0102)

    Kansas City, Kansas

  • Lexington VA Medical Center - Cooper Division ( Site 0137)

    Lexington, Kentucky

  • Corewell Health ( Site 0133)

    Grand Rapids, Michigan

  • Mayo Clinic in Rochester, Minnesota ( Site 0131)

    Rochester, Minnesota

  • Creighton University Clinical Research Office ( Site 0123)

    Omaha, Nebraska

  • University of New Mexico Hospital ( Site 0146)

    Albuquerque, New Mexico

  • UNC Health - Eastowne Medical Office-Clinical Trials Unit ( Site 0147)

    Chapel Hill, North Carolina

  • Temple University Hospital ( Site 0104)

    Philadelphia, Pennsylvania

  • UPMC Montefiore University Hospital-Department of Medicine ( Site 0149)

    Pittsburgh, Pennsylvania

  • UT Southwestern Medical Center ( Site 0114)

    Dallas, Texas

  • The University of Texas Health Science Center at Houston ( Site 0105)

    Houston, Texas

  • Intermountain Medical Center-Division of Pulmonary & Critical Care Medicine ( Site 0140)

    Murray, Utah

  • University of Virginia Health System-Division of Pulmonary and Critical Care Medicine ( Site 0111)

    Charlottesville, Virginia

  • Hospital Britanico de Buenos Aires ( Site 0307)

    CABA, Argentina

  • Hospital Privado Universitario de Córdoba-Clinical Cardiology Department ( Site 0302)

    Córdoba, Argentina

  • Fundación Respirar ( Site 0305)

    CABA, Buenos Aires, Argentina

  • Centro Medico Capital ( Site 0301)

    La Plata, Buenos Aires, Argentina

  • Instituto de Cardiologia de Tucuman-Area de Investigacion Clinica ( Site 0303)

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Royal Prince Alfred Hospital-Department of Respiratory Medicine ( Site 0903)

    Camperdown, New South Wales, Australia

  • Westmead Hospital ( Site 0902)

    Westmead, New South Wales, Australia

  • WESLEY RESEARCH INSTITUTE Limited ( Site 0906)

    Auchenflower, Queensland, Australia

  • The Prince Charles Hospital ( Site 0904)

    Brisbane, Queensland, Australia

  • Mater Misericordiae Limited ( Site 0905)

    South Brisbane, Queensland, Australia

  • Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 1201)

    Graz, Styria, Austria

  • Medizinische Universitaet Innsbruck ( Site 1202)

    Innsbruck, Tyrol, Austria

  • Université Libre de Bruxelles - Hôpital Erasme ( Site 1302)

    Brussels, Bruxelles-Capitale, Region de, Belgium

  • UZ Leuven ( Site 1301)

    Leuven, Vlaams-Brabant, Belgium

  • Clinica Cardio VID ( Site 0504)

    Medellín, Antioquia, Colombia

  • Ciensalud Ips S A S ( Site 0508)

    Barranquilla, Atlántico, Colombia

  • Fundación Valle del Lili ( Site 0509)

    Cali, Valle del Cauca Department, Colombia

  • Centro de Investigaciones Clinicas SAS ( Site 0505)

    Cali, Valle del Cauca Department, Colombia

  • C.H.U Hôpital Nord ( Site 1503)

    Marseille, Bouches-du-Rhone, France

  • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois ( Site 1502)

    Vandœuvre-lès-Nancy, Lorraine, France

  • CHU Angers ( Site 1506)

    Angers, Maine-et-Loire, France

  • Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre-Pneumologie ( Site 1501)

    Le Kremlin-Bicêtre, Paris, France

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.